DE3341760C2 - - Google Patents

Info

Publication number
DE3341760C2
DE3341760C2 DE3341760A DE3341760A DE3341760C2 DE 3341760 C2 DE3341760 C2 DE 3341760C2 DE 3341760 A DE3341760 A DE 3341760A DE 3341760 A DE3341760 A DE 3341760A DE 3341760 C2 DE3341760 C2 DE 3341760C2
Authority
DE
Germany
Prior art keywords
pepsin
human
enzyme
human leukocyte
leukocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3341760A
Other languages
German (de)
English (en)
Other versions
DE3341760A1 (de
Inventor
Haruo Funabashi Chiba Jp Ohnishi
Hiroshi Yokohama Kanagawa Jp Kosuzume
Yasuo Kawaguchi Saitama Jp Suzuki
Ei Tokio/Tokyo Jp Mochida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Publication of DE3341760A1 publication Critical patent/DE3341760A1/de
Application granted granted Critical
Publication of DE3341760C2 publication Critical patent/DE3341760C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19833341760 1982-11-20 1983-11-18 Arzneimittel mit einer phagocyten-kontrollwirkung Granted DE3341760A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57203990A JPS5995221A (ja) 1982-11-20 1982-11-20 食細胞機能調節作用を有する医薬組成物

Publications (2)

Publication Number Publication Date
DE3341760A1 DE3341760A1 (de) 1984-06-14
DE3341760C2 true DE3341760C2 (US08197722-20120612-C00042.png) 1989-09-07

Family

ID=16482949

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19833341760 Granted DE3341760A1 (de) 1982-11-20 1983-11-18 Arzneimittel mit einer phagocyten-kontrollwirkung

Country Status (11)

Country Link
US (1) US4534966A (US08197722-20120612-C00042.png)
JP (1) JPS5995221A (US08197722-20120612-C00042.png)
AU (1) AU552756B2 (US08197722-20120612-C00042.png)
CA (1) CA1204054A (US08197722-20120612-C00042.png)
CH (1) CH657050A5 (US08197722-20120612-C00042.png)
DE (1) DE3341760A1 (US08197722-20120612-C00042.png)
FR (1) FR2536281B1 (US08197722-20120612-C00042.png)
GB (1) GB2132481B (US08197722-20120612-C00042.png)
IT (1) IT1174799B (US08197722-20120612-C00042.png)
NL (1) NL8303980A (US08197722-20120612-C00042.png)
SE (1) SE460825B (US08197722-20120612-C00042.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309072B2 (en) * 2004-11-12 2012-11-13 The Zhabilov Trust Irreversibly-inactivated pepsinogen fragments for modulating immune function
US8067531B2 (en) 2004-11-12 2011-11-29 The Zhabilov Trust Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells
WO2007041285A2 (en) * 2005-09-29 2007-04-12 Viral Genetics, Inc. Complexes of inactivated pepsin fraction and heat shock protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR59346E (fr) * 1949-06-09 1954-05-24 Valise roulante
US2930736A (en) * 1957-01-07 1960-03-29 Nat Drug Co Stabilized trypsin compositions containing partially hydrolyzed gelatin and method of making
FR2119872A1 (fr) * 1970-12-30 1972-08-11 Kuban Med I Im Krasnoi Armii Produit a base de pepsine,notamment pour le traitement des maladies s'accompagnant d'une insuffisance secretoire de l'estomac
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
CA1181005A (en) * 1981-02-10 1985-01-15 Haruo Ohnishi Therapeutic agent for treatment of allergic diseases, immune complex diseases and tumors
NL8220027A (nl) * 1982-02-09 1983-11-01 Mochida Pharm Co Ltd Therapeutisch middel voor de behandeling van allergische aandoeningen, immuno.complexziekten en tumoren.
AU8459882A (en) * 1982-05-31 1983-12-16 Mochida Pharmaceutical Co., Ltd. Human leukocyte pepsin-like enzyme, and a therapeutic agent containing said enzyme as effective ingredient for treating allergic disorder, immune complex disease, and tumor

Also Published As

Publication number Publication date
IT1174799B (it) 1987-07-01
AU552756B2 (en) 1986-06-19
CA1204054A (en) 1986-05-06
AU2155483A (en) 1984-05-24
CH657050A5 (de) 1986-08-15
SE460825B (sv) 1989-11-27
JPH0261925B2 (US08197722-20120612-C00042.png) 1990-12-21
GB2132481A (en) 1984-07-11
JPS5995221A (ja) 1984-06-01
GB2132481B (en) 1987-02-11
FR2536281B1 (fr) 1989-05-12
US4534966A (en) 1985-08-13
IT8349367A0 (it) 1983-11-21
SE8306384L (sv) 1984-05-21
GB8330810D0 (en) 1983-12-29
DE3341760A1 (de) 1984-06-14
SE8306384D0 (sv) 1983-11-18
NL8303980A (nl) 1984-06-18
FR2536281A1 (fr) 1984-05-25

Similar Documents

Publication Publication Date Title
US5079236A (en) Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
Dhuley Effect of ashwagandha on lipid peroxidation in stress-induced animals
DE69434414T2 (de) Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung
DE60103066T2 (de) Chlorella zubereitungen mit immunmodulatorischen eigenschaften
DE69530910T4 (de) Medizinische zusammensetzungen enthaltend ein sialinsäurederivat
EP1429789B1 (de) Antiinfektive kohlenhydrate
DE69010162T2 (de) Zusammensetzung zur Behandlung von Entzündung.
DE3001585A1 (de) Verfahren zur herstellung von interferon typ ii und es enthaltende zubereitungen
DD202804A5 (de) Verfahren zur herstellung eines mittels zur vorbeugung und behandlung von leber- und nierenerkrankungen
DD209634A5 (de) Verfahren zur herstellung neuer glykoproteine und deren verwendung in therapeutischen mitteln gegen tumore
DE3418820C2 (US08197722-20120612-C00042.png)
AT397615B (de) Arzneimittel enthaltend protein c
DE69919302T2 (de) Immunomodulator enthaltend bakterielle Zellen oder Abbauprodukte ihrer Zellwände
DE3341760C2 (US08197722-20120612-C00042.png)
DE69031694T3 (de) Glutamin zur Behandlung von beeinträchtigten Abwehrkräften
DE68909019T2 (de) Virushemmende Zusammensetzung und ihre Anwendungen.
DE3750464T2 (de) Pharmazeutisches Präparat zur Behandlung des Katarakts.
DE68903065T2 (de) Aus gingko biloba extrahierter biologischer regulator, wirksam in verschiedenen pathologien.
DE68918562T2 (de) Menschliche myeloperoxidase und therapeutische verwendung.
DE2605576C3 (de) Verfahren zum Isolieren der Proteasen Papain,,Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und Iyophilisirten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten
DE69011465T2 (de) Verwendung von Human-ADF (=Adult T-cell leukemia-derived factor) zur Herstellung von Medikamenten.
DE69918953T2 (de) Zusammensetzung von oligosacchariden zur regulierung von apoptose
DE69633040T2 (de) Inhibitor der hornhaut-vaskularisation
DE1617279C3 (de) Verfahren zur Herstellung eines die Aspergillopeptidase ARL 1 enthaltenden Präparates aus Aspergillus oryzae und sie enthaltendes Arzneimittel
DE69004941T2 (de) Arzneimittelformulierungen zum Erhöhen der Wirksamkeit von Betalaktamantibiotika in Prophylaxe und Behandlung von infektiöser Krankheit infolge pathogener Bakterien.

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee